home / stock / ivevf / ivevf news

IVEVF News and Press, Inventiva From 07/02/25

Stock Information
Company Name: Inventiva
Stock Symbol: IVEVF
Market: OTC
Website: inventivapharma.com
Menu
IVEVF IVEVF Quote IVEVF Short IVEVF News IVEVF Articles IVEVF Message Board
Get IVEVF Alerts

News, Short Squeeze, Breakout and More Instantly...
IVEVF - Inventiva announces the publication in Journal of Hepatology Reports on results of lanifibranor treatment on liver sinusoidal endothelial cells in patients with MASLD/MASH and in preclinical models of the disease

Analysis of liver sinusoidal endothelial cells (“LSEC”) from screening and end of treatment biopsies in the Phase 2b NATIVE study showed evidence of LSEC capillarization in patients without MASH, and a further increased capillarization in patients with MASH In addition, in t...
IVEVF - Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Directors

Daix (France), New York City (New York, United States), June 10, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of meta...

IVEVF - Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference

Daix (France), New York City (New York, United States), May 27, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment ...

IVEVF - Inventiva S.A. reports Q1 results

2025-05-23 10:32:37 ET More on Inventiva S.A Inventiva S.A. (IVA) Q4 2024 Earnings Call Transcript Seeking Alpha’s Quant Rating on Inventiva S.A Historical earnings data for Inventiva S.A Financial information for Inventiva S.A Read the full ...
IVEVF - Inventiva reports 2025 First Quarter Financial Information¹

Cash and cash equivalents at €67.9 million Daix (France), New York City (New York, United States), May 23, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral...

IVEVF - Results of the Votes of the Combined Shareholders' General Meeting of May 22, 2025

Daix (France), New York City (New York, United States), May 23, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated s...

IVEVF - Description of the Share Repurchase Program Covered by the Liquidity Agreement with Kepler Chevreux

Daix, May 22, 2025 Pursuant to Article 241-2 of the AMF General Regulations ( Règlement Général de l’Autorité des marchés financiers ), the purpose of this description is to present the objectives and terms of the Company’s share repurchase program a...
IVEVF - Inventiva secures Euro116 million second tranche of structured financing of up to Euro348 million

2025-05-05 03:44:05 ET More on Inventiva S.A. Inventiva S.A. (IVA) Q4 2024 Earnings Call Transcript Historical earnings data for Inventiva S.A. Financial information for Inventiva S.A. Read the full article on Seeking Alpha For further details see: ...

IVEVF - Inventiva secures the Euro116 million second tranche of its structured financing of up to Euro348 million

Financing follows completion of enrollment of Phase 3 NATiV3 study evaluating lanifibranor in MASH and satisfaction of other specified conditions. Daix (France), New York City (New York, United States), May 5, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“ ...

IVEVF - Combined General Meeting of May 22, 2025 - Availability of the preparatory documents

Daix (France), New York City (New York, United States), April 30,  2025 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohe...
Previous 10 Next 10